Header Logo

Connection

BRYAN BURT to Mesothelioma

Back to Details
This is a "connection" page, showing publications BRYAN BURT has written about Mesothelioma.
BRYAN BURT
Connection Strength
10.180
Mesothelioma
  1. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023 02 01; 29(3):548-559.
    View in: PubMed
    Score: 0.722
  2. Checkpoint blockade in unresectable pleural mesothelioma: Event horizon for multimodal therapy. J Thorac Cardiovasc Surg. 2023 01; 165(1):364-368.
    View in: PubMed
    Score: 0.672
  3. Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma. Ann Thorac Surg. 2021 11; 112(5):1575-1583.
    View in: PubMed
    Score: 0.621
  4. Commentary: Focused attention on proactive identification of deep venous thrombosis after pleurectomy/decortication for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2020 10; 160(4):1075-1076.
    View in: PubMed
    Score: 0.584
  5. Preoperative prediction of unresectability in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2020 06; 159(6):2512-2520.e1.
    View in: PubMed
    Score: 0.579
  6. To slay a dragon: Timing of chemotherapy in resectable pleural mesothelioma. J Thorac Cardiovasc Surg. 2019 02; 157(2):767-768.
    View in: PubMed
    Score: 0.538
  7. A thinner peel to peel: Pleural thickness is prognostic in mesothelioma. J Thorac Cardiovasc Surg. 2019 01; 157(1):414-415.
    View in: PubMed
    Score: 0.536
  8. A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma. J Thorac Oncol. 2018 09; 13(9):1400-1409.
    View in: PubMed
    Score: 0.520
  9. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight. 2018 04 05; 3(7).
    View in: PubMed
    Score: 0.517
  10. Therapeutic R2 resection for pleural mesothelioma. J Thorac Cardiovasc Surg. 2018 06; 155(6):2734-2735.
    View in: PubMed
    Score: 0.511
  11. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma. Ann Thorac Surg. 2017 Nov; 104(5):1679-1687.
    View in: PubMed
    Score: 0.499
  12. Invited Commentary. Ann Thorac Surg. 2015 Nov; 100(5):1874.
    View in: PubMed
    Score: 0.437
  13. CTLA4 blockade in patients with malignant mesothelioma. Lancet Respir Med. 2015 Apr; 3(4):261-3.
    View in: PubMed
    Score: 0.419
  14. Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality. J Thorac Cardiovasc Surg. 2014 Jul; 148(1):30-5.
    View in: PubMed
    Score: 0.390
  15. Clinical indications and results after chest wall resection for recurrent mesothelioma. J Thorac Cardiovasc Surg. 2013 Dec; 146(6):1373-9; discussion 1379-80.
    View in: PubMed
    Score: 0.379
  16. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin Cancer Res. 2012 Mar 15; 18(6):1568-77.
    View in: PubMed
    Score: 0.336
  17. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer. 2011 Nov 15; 117(22):5234-44.
    View in: PubMed
    Score: 0.319
  18. Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy. J Thorac Cardiovasc Surg. 2025 Apr; 169(4):1082-1095.e4.
    View in: PubMed
    Score: 0.203
  19. Pleurectomy and decortication are associated with better survival for bicavitary cytoreductive surgery for mesothelioma compared with extrapleural pneumonectomy. J Thorac Cardiovasc Surg. 2023 05; 165(5):1722-1730.
    View in: PubMed
    Score: 0.179
  20. Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors. Clin Cancer Res. 2022 12 01; 28(23):5121-5135.
    View in: PubMed
    Score: 0.178
  21. A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma. Br J Cancer. 2022 11; 127(9):1691-1700.
    View in: PubMed
    Score: 0.175
  22. Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma. Ann Thorac Surg. 2022 11; 114(5):1842-1852.
    View in: PubMed
    Score: 0.164
  23. Reply to Waller et?al. Standardizing Surgical Treatment for Mesothelioma. J Thorac Oncol. 2020 05; 15(5):e75-e77.
    View in: PubMed
    Score: 0.149
  24. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731.
    View in: PubMed
    Score: 0.142
  25. A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. J Thorac Oncol. 2019 08; 14(8):1343-1353.
    View in: PubMed
    Score: 0.140
  26. Commentary: Adjuvant intensity-modulated radiation therapy for malignant pleural mesothelioma: Suspension of intention. J Thorac Cardiovasc Surg. 2019 09; 158(3):932-933.
    View in: PubMed
    Score: 0.138
  27. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667.
    View in: PubMed
    Score: 0.133
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.